Since launching AVISE CTD in 2012, Exagen has produced an extensive body of peer-reviewed literature supporting the test’s clinical validity and utility. These publications and the 1,000,000 th ...

Exagen (XGN) announced the completion of its 1,000,000th AVISE CTD test, marking a significant milestone that underscores the company’s ...

Dec. 12, 2024 (GLOBE NEWSWIRE) -- Exagen Inc., a leading provider of autoimmune testing, today announced the completion of its 1,000,000 th AVISE CTD test, marking a significant milestone that ...